Compare Neurocrine Biosciences Inc (NBIX) vs Palantir Technologies Inc (PLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Palantir Technologies Inc — how do they compare? Neurocrine Biosciences Inc trades at $179.88 (market cap $17.40B), while Palantir Technologies Inc trades at $132.2 (market cap $323.28B). The key difference: Palantir Technologies Inc is far larger — about 18.6× Neurocrine Biosciences Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Palantir Technologies Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | PLTR | |
|---|---|---|
Market Cap | $17.40B | $323.28B |
Sector | Health | Technology |
52-Week High | $180.55 | $207.18 |
52-Week Low | $123.10 | $107.27 |
Enterprise Value | $16.49B | $315.46B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →
